Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#3885 Adaptive immunosuppressive resistance mechanisms towards antiangiogenic immunotherapies revealed in a pancreatic neuroendocrine tumor (PNET) model

Introduction: Pancreatic neuroendocrine tumors (PNETs) are mostly indolent but can achieve malignancy. Surgery is the only approved first-line therapy. Kinase inhibitors and radiotherapy for unresectable PNETs are non-curative and targeted therapies are currently lacking for PNETs. However, immune checkpoint inhibitors have created a paradigm shift in cancer therapy with significant increase in overall survival, but are curative only in a subset of patients, partly due to limited T cell infiltration, especially in angiogenic and cold tumors like PNETs. Parallelly, antiangiogenic therapy increases lymphocyte infiltration by normalising the tumor vasculature. Tallying antiangiogenic to immunotherapies (AI) has provided improved survival benefits for patients of advanced RCCs and HCCs, while other cancers like glioblastoma remain highly resistant.

Conference:

Presenting Author:

Authors: John Robbert D, Guyot M, Killian T, Verslype C, Lambrechts D,

Keywords: Pancreatic neuroendocrine tumor, Antiangiogenic immunotherapy, single cell transcriptomics, Immunosuppression,